Navigation Links
BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
Date:8/22/2007

Molecular Chaperones Target Underlying Defect in Cystic Fibrosis; CFTR

Folding and Transport

NOVATO, Calif., Aug. 22 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has licensed from the University of California, San Francisco (UCSF) intellectual property covering compounds demonstrated to improve cystic fibrosis transmembrane conductance regulator (CFTR) protein functionality. BioMarin expects the lead compounds to undergo additional animal testing and optimization, with the goal of filing an IND in 2009.

Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin commented. "Dr. Verkman's laboratory has performed pioneering work in the field of CFTR modulation. The compounds licensed have been developed through a rigorous high-throughput screening process and have demonstrated a high degree of potency and specificity for the folding and activation of the abnormal CFTR protein. We look forward to accelerating the lead optimization activities in collaboration with Dr. Verkman and his colleagues so that we can take the very best of these molecules into clinical development."

"Over the last decade, considerable efforts and funding from the Cystic Fibrosis Foundation and the biotechnology industry have resulted in the development of therapeutics that have significantly extended and improved the lives of cystic fibrosis patients," said Dr. Alan Verkman, Professor of Medicine and Physiology and Director of the Cystic Fibrosis Research Development Program at the University of California, San Francisco. "Despite this progress, there is no therapeutic approved that addresses the underlying molecular defect in cystic fibrosis, and most patients succumb to respiratory failure as young adults. BioMarin has a strong track record of aggressively moving disease modifying therapeutics through clinical development, and I am very pleased that they have made a commitment to fur
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GenTel licenses next generation cancer research
2. Third Wave licenses Innogenetics tech to settle lawsuit
3. WARF licenses patents for new glaucoma drug treatment
4. PKWARE Licenses Technology to Expand SecureZIP Standard
5. Mentor Licenses Botulinum From WARF and Plans Wisconsin Manufacturing Facility
6. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
7. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
8. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
9. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
10. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
11. Use of FlashPlate Technology for In Vitro Measurement of [35S]-GTPγS Binding in CHO Cells Expressing the Human 5-HT1B Receptor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... SHANGHAI , Aug. 31, 2015 ... developing next-generation antibiotics, today announced positive top-line results ... its lead drug candidate MRX-I. MRX-I is an ... such as MRSA and VRE, while offering physicians ... option than currently available oxazolidinone agents. ...
(Date:8/31/2015)... Trimb Healthcare AB ("Trimb") today announced that it has ... a Dutch OTC company with operations in key European ... 16 million, with solid growth and leading brands in ... build a leading international OTC company, and this acquisition ... us a stronger North European OTC platform, from which ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment ... is the first commercially available new FDA approved system in the last 14 years, ... 92%, the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Global & USA ... offering. The highly awaited US Biosimilar market ... highly awaited filigrastim biologic, Zarxio. How will the global ... The author reveals that biosimilars could save the US ...
Breaking Biology Technology:MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3
... Health Care Compliance Strategies, Inc. (HCCS) , ... training, today announced the release of a new online ... Associates (BAs) . Responding to expanded HIPAA Privacy Rule ... an online course designed to assist healthcare vendors in ...
... , a venture backed clinical stage biotechnology company developing ... from the Phase 2b trial of ARC-4558 for the ... will be the subject of two poster presentations at ... at the American Diabetes Association,s 71st Scientific Sessions, June ...
... Reportlinker.com announces that a new market research ... Global Immunochemicals Industry ... report analyzes the worldwide markets for Immunochemicals ... segments – Catalog Antibodies, and Custom Antibodies. ...
Cached Biology Technology:New Online Training Course Helps Healthcare Vendors Comply with HIPAA Regulations 2New Online Training Course Helps Healthcare Vendors Comply with HIPAA Regulations 3Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings 2Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings 3Reportlinker Adds Global Immunochemicals Industry 2Reportlinker Adds Global Immunochemicals Industry 3Reportlinker Adds Global Immunochemicals Industry 4Reportlinker Adds Global Immunochemicals Industry 5Reportlinker Adds Global Immunochemicals Industry 6Reportlinker Adds Global Immunochemicals Industry 7Reportlinker Adds Global Immunochemicals Industry 8Reportlinker Adds Global Immunochemicals Industry 9Reportlinker Adds Global Immunochemicals Industry 10
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Saudi Arabia Biomedical Sensors Market - ... offering. The Saudi Arabia Biomedical Sensors ... a CAGR of 3.64% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:8/24/2015)... The consulting company Frost & Sullivan ... DERMALOG and its customized solutions and products for ... the Year Award". DERMALOG is particularly successful with a large ... -Cross reference: Picture is available at AP Images ( ... Thursday evening, in South Africa,s economic ...
(Date:8/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... Smart Card Alliance and the EMV Migration Forum.  ... Smart Card Alliance Latin America (SCALA) Chapter provides NXT-ID, ... thought leaders promoting adoption of smart card technology. ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... (self-donated) mononuclear cells derived from bone marrow (BMMNCs) have ... into patients with diabetes who are suffering from critical ... complication of diabetes. The team of researchers in Seville, ... in a recent issue of Cell Transplantation ...
... of Alberta is working with scientists from across North America to ... 15 scientists will examine DNA samples from children with autism and ... risk. , , And if siblings are at high risk ... , If theres a family of a child with autism, they ...
... Boston In a breakthrough for the way brain cancer ... Anna M. Krichevsky, PhD, of the Center of Neurologic Diseases ... Kesari, MD, PhD, director of Neuro-Oncology at UC San Diego ... reliably diagnosed and monitored without surgery. Previously, an accurate ...
Cached Biology News:Autologous bone marrow-derived mononuclear cell transplants can reduce diabetic amputations 2Researchers across North America team up to find genetic markers for autism 2
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
... of an N-terminal FLAG® fusion and a ... from bicistronic mRNA. Two genes can ... transcription of a single message from the ... protein-protein interaction studies, multi-subunit proteins, and cloning ...
Mouse monoclonal antibody raised against a partial recombinant CALCOCO2. NCBI Entrez Gene ID = CALCOCO2...
Biology Products: